Medicare GLP-1 Bridge reported as an inflection point in month one
Access expanded to roughly 20 million eligible beneficiaries, with prior authorisation reportedly running smoothly.
Access expanded to roughly 20 million eligible beneficiaries, with prior authorisation reportedly running smoothly.
All-in monthly cost at 10 mg
On its second-quarter call Lilly reported the Bridge — live since 1 July 2026 — is expanding access to about 35% more Americans, with a significant inflection in prescriptions and roughly 80% of new patients choosing injectables.
If you are Medicare-eligible and paying cash for compounded tirzepatide, a flat $50 monthly co-pay for an FDA-approved product is below every compounded route we track.
Eligibility is set by your specific Part D plan rather than by the headline. Verify with the plan.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.